Taiyen Biotech Co Ltd (TW:1737) — Market Cap & Net Worth
Market Cap & Net Worth: Taiyen Biotech Co Ltd (1737)
Taiyen Biotech Co Ltd (TW:1737) has a market capitalization of $200.69 Million (NT$6.37 Billion) as of May 4, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #16519 globally and #792 in its home market, demonstrating a -0.93% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Taiyen Biotech Co Ltd's stock price NT$31.85 by its total outstanding shares 200000000 (200.00 Million). Analyse Taiyen Biotech Co Ltd operating cash flow efficiency to see how efficiently the company converts income to cash.
Taiyen Biotech Co Ltd Market Cap History: 2015 to 2026
Taiyen Biotech Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $143.50 Million to $200.69 Million (5.44% CAGR).
Taiyen Biotech Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Taiyen Biotech Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.06x
Taiyen Biotech Co Ltd's market cap is 0.06 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.50x
Taiyen Biotech Co Ltd's market cap is 0.50 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $145.40 Million | $2.76 Billion | $351.97 Million | 0.05x | 0.41x |
| 2017 | $145.80 Million | $2.76 Billion | $353.69 Million | 0.05x | 0.41x |
| 2018 | $155.78 Million | $3.00 Billion | $452.74 Million | 0.05x | 0.34x |
| 2019 | $179.41 Million | $2.91 Billion | $345.50 Million | 0.06x | 0.52x |
| 2020 | $189.31 Million | $3.13 Billion | $365.08 Million | 0.06x | 0.52x |
| 2021 | $200.07 Million | $4.10 Billion | $393.23 Million | 0.05x | 0.51x |
| 2022 | $204.47 Million | $3.61 Billion | $426.70 Million | 0.06x | 0.48x |
| 2023 | $215.50 Million | $3.41 Billion | $300.39 Million | 0.06x | 0.72x |
| 2024 | $204.47 Million | $3.24 Billion | $371.52 Million | 0.06x | 0.55x |
| 2025 | $199.74 Million | $3.31 Billion | $399.87 Million | 0.06x | 0.50x |
Competitor Companies of 1737 by Market Capitalization
Companies near Taiyen Biotech Co Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Taiyen Biotech Co Ltd by market ranking:
- Procter & Gamble Company (NYSE:PG): Ranked #41 globally with a market cap of $344.11 Billion USD.
- LOREAL ADR 1/5/EO 02 (F:LORA): Ranked #95 globally with a market cap of $204.17 Billion USD ( €174.64 Billion EUR).
- L’Oreal SA (PA:OR): Ranked #104 globally with a market cap of $198.75 Billion USD ( €170.01 Billion EUR).
- Colgate-Palmolive Company (NYSE:CL): Ranked #382 globally with a market cap of $70.34 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #41 | Procter & Gamble Company | NYSE:PG | $344.11 Billion | $147.26 |
| #95 | LOREAL ADR 1/5/EO 02 | F:LORA | $204.17 Billion | €72.00 |
| #104 | L’Oreal SA | PA:OR | $198.75 Billion | €366.05 |
| #382 | Colgate-Palmolive Company | NYSE:CL | $70.34 Billion | $87.26 |
Taiyen Biotech Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Taiyen Biotech Co Ltd's market cap moved from $143.50 Million to $ 200.69 Million, with a yearly change of 5.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$200.69 Million | +0.47% |
| 2025 | NT$199.74 Million | -2.31% |
| 2024 | NT$204.47 Million | -5.12% |
| 2023 | NT$215.50 Million | +5.39% |
| 2022 | NT$204.47 Million | +2.20% |
| 2021 | NT$200.07 Million | +5.69% |
| 2020 | NT$189.31 Million | +5.52% |
| 2019 | NT$179.41 Million | +15.17% |
| 2018 | NT$155.78 Million | +6.84% |
| 2017 | NT$145.80 Million | +0.28% |
| 2016 | NT$145.40 Million | +1.33% |
| 2015 | NT$143.50 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Taiyen Biotech Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $200.69 Million USD |
| MoneyControl | $200.69 Million USD |
| MarketWatch | $200.69 Million USD |
| marketcap.company | $200.69 Million USD |
| Reuters | $200.69 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Taiyen Biotech Co Ltd
Taiyen Biotech Co., Ltd. engages in the production and sale of salt products in Taiwan and internationally. It offers beauty and skincare, and cleaning products; salt products; and leisure and pet foods, as well as health supplement. The company was founded in 1952 and is based in Tainan City, Taiwan.